Eli Lilly and Company (LLY)
| Market Cap | 704.75B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 63.88 |
| Forward PE | 31.46 |
| Dividend | $6.00 (0.76%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 2,442,736 |
| Open | 789.95 |
| Previous Close | 791.24 |
| Day's Range | 779.44 - 790.63 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 1,014.22 (+29.2%) |
| Earnings Date | Aug 7, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,014.22, which is an increase of 29.20% from the latest price.
News
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve...
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug
Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country'...
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced ...
Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics
Eli Lilly's $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine. The pharmaceutical behemoth paid a substantial premium of approximately 113...
Lilly to buy gene-editing partner Verve for $1.3 billion
CNBC's Angelica Peebles reports on the latest news surrounding Eli Lilly.
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.
JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV
Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Even though oncology, the segment in which the acquisition was made, has...
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Verve Therapeutics' stock rallies by a record 80% on Eli Lilly's premium purchase price for the drug-development company.
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardi...
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.
A report said the two pharmaceutical companies are in advance talks.
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Lilly to offer higher dose versions of weight-loss drugs on website
U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug Zepbound on its website LillyDirect.
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Jour...
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on...
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.
Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's Disruptor 50 List.
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Research will leverage world's first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the discov...
Drug pricing reform talks with US government lack clarity, industry executives say
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at...
Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Eli Lilly and Company (NYSE:LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director ...
The Highest-Quality Dividend Contenders By Quality Scores
The article presents the highest-quality Dividend Contenders, companies listed on U.S. exchanges with higher annual dividend payouts for 10-24 consecutive years. I use a quality scoring system with si...
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.